Content is not available

Calithera Biosciences

South San Francisco,  CA 
United States
https://www.calithera.com/pipeline/
  • Booth: 11048a

Calithera is developing targeted small molecules to disrupt tumor metabolism. Telaglenastat, a glutaminase inhibitor, in combination with chemoimmunotherapy is being evaluated in a randomized 1L trial in patients with NSCLC with KEAP1/NRF2 mutations.

 Products

  • KEAPSAKE Trial Now Enrolling
    A Phase 2, Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab (Keytruda®) and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC) (NCT04265534)...

Categories

Cancer Types
  • Lung Cancer
  • Metastatic Disease
    • Categories:
  • Biomarkers
  • Clinical Trials
  • Developmental Therapeutics
    • << Previous Back to the Search Next >>
    Loading ...

    :
    :


    Legend
    Available Timeslot
    Scheduled Appointment
    Personal Appointments
    Request
    Blocked Timeslot
    Restricted Timeslot
    Cancelled
    Declined